Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 15, 2003

View Archived Issues

New therapeutic target for type 2 diabetes: beta-cell apoptosis

Spotlight on PPAR agonists in development for diabetes mellitus

Spotlight on contraceptive research

New beta3-adrenoceptor agonists for urinary incontinence and other uses

Potassium channel-modulating series described by 4SC researchers

Selective progesterone receptor modulators prepared and tested at Schering AG

Wyeth presents new estrogenic agents with potential in menopause, endometriosis, etc.

Medinox patent covers novel NSAID prodrugs with improved safety profile

Bayer presents new p38 kinase inhibitors for COPD therapy

Seroquel approved in Europe for bipolar mania

Oral dosing of AVI-4557 tested in phase I study

Betaseron prefilled diluent syringe receives FDA approval

IPM grant to advance cyanovirin-N development

Bristol-Myers Squibb and Corgentech to jointly develop E2F decoy

Independent data support use of M6G for postoperative pain

Dual-acting anthrax vaccine designed by Boston-based team

ChemoCentryx awarded grant to develop chemokine-based immunomodulators

Wyeth advances NSP-989 into phase II

New data supports Cialis for ED

Metabolic licenses analgesic compound discovered at university

Preliminary observations from European trials of Hynic-Annexin V product

PEG-Intron Redipen approved by FDA

VaxGen enters license agreement with USAMRIID for vaccine technology

Selective erbB2 kinase inhibitor CP-654577 inhibits growth of human breast cancer

Flatfish-derived antimicrobial peptide discovered using genomic approach

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 16, 2025.
Zusduri flurry ends; ‘set up’ at ODAC, Urogen prevails with FDA
BioWorld
During a conference call after the U.S. FDA approval of Zusduri (mitomycin), Urogen Pharma Ltd. CEO Liz Barrett offered candid observations about a...
23andme founder-led group outbids Regeneron for company
BioWorld
The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...
Elevidys’ second liver death hits Sarepta, sends DMD ripples
BioWorld
How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...